Today, news outlets reported that Donald Trump plans to nominate White House Domestic Policy Deputy Director Dr. Heidi Overton — an anti-abortion extremist who celebrated the Supreme Court overturning the right to abortion — to serve as his Food and Drug Administration (FDA) Commissioner. The FDA plays a critical role in safeguarding the health of people across the country, including by making science-based decisions about medication abortion, birth control, and other essential reproductive healthcare.
Overton has an extensive anti-abortion record. She celebrated the overturning of Roe v. Wade as a “huge victory,” and has advocated for the politicization of government agencies to help advance a nationwide anti-abortion agenda. She previously worked at America First Policy Institute, an extreme conservative think tank made up of former Trump administration officials, where she authored a brief pushing disinformation about the safety of medication abortion and calling for additional, medically unnecessary restrictions on access to mifepristone.
Overton’s nomination comes as the FDA rushes to advance a politically motivated, sham “study” of mifepristone, and remains under close scrutiny from anti-abortion groups and leaders who relentlessly demand that the agency takes decisive action to restrict access to medication abortion care.
Reproductive Freedom for All President and CEO Mini Timmaraju released the following statement:
“Donald Trump is trying to put an anti-abortion extremist in charge of any agency that could seriously undermine reproductive healthcare—including the agency that could roll back access to mifepristone nationwide. Heidi Overton celebrated the fall of Roe, spread junk science about medication abortion, and openly called for remaking the FDA to serve a political agenda instead of the health of the country. Her nomination is another alarming step in Trump’s plan to weaponize every part of the federal government to restrict abortion nationwide.”
If confirmed, Overton would succeed Martin Makary, who resigned as FDA Commissioner in May. Initial reports of Makary’s departure from the FDA emerged just after a meeting between White House staff and anti-abortion groups, who expressed frustration the FDA has not sufficiently wielded its power to ban mifepristone outright. Anti-abortion groups then shifted their demands to acting FDA Commissioner Kyle Diamantas, who called anti-abortion leaders within hours of being appointed and said that accelerating the review was his top priority.